<html hola_ext_inject="disabled" xmlns="http://www.w3.org/1999/xhtml" xmlns:hwui="http://schema.highwire.org/Site/UI">
<head>
  <title>ASCO 2017: Sharing Knowledge - The Oncologist</title>
</head>
<body>
<div id="begin-content-marker"><!-- start of content marker div --></div>
<!-- * Begin editable area * -->

<div id="proxied-contents">
<h1 style="margin-top:15px;">Sharing Knowledge: Precision Oncology</h1>

<div class="caption"><img src="/preview_site/Images/Chabner-WB.jpg" style="float: right; height: 189px; width: 130px;" />
<p>Bruce A. Chabner, M.D.</p>
</div>


<p style="margin-bottom:30px;">We present here a sample of the kind of information available through reading the pages of <em><strong>The Oncologist</strong></em>. Our challenge is to bring you the latest and most interesting articles, covering a wide range of topics relevant to the practice of our specialty: genomics, immunology, global challenges, early clinical trials, and regulatory actions cover only a fraction of subjects covered in the rapidly changing spectrum of developments in our field. Give us a few minutes of your day, and send us your feedback at TheOncologist.com. We aim to inspire you and keep you informed.</p>

<p>Jump to section:<br />
<a href="#breast">Breast Cancer</a> | <a href="#diagnostics">Cancer Diagnostics and Molecular Pathology</a> | <a href="#endocrinology">Endocrinology</a> | <a href="#gastrointestinal">Gastrointestinal Cancer</a> | <a href="#genitourinary">Genitourinary Cancer</a> | <a href="#globalhealth">Global Health and Cancer</a> | <a href="#gynecologic">Gynecologic Oncology</a> | <a href="#lung">Lung Cancer</a> | <a href="#melanoma">Melanoma and Cutaneous Malignancies</a> | <a href="#radiation">Radiation Oncology</a> | <a href="#sarcomas">Sarcomas</a> | <a href="#precision">Precision Medicine Clinic</a> 
  
  </p>

  <style type="text/css">h2 {
  color: #967199;
  border-bottom: 1px solid #4c4c4c;    
}
    
.caption { 
  padding: 10px; font-style: italic; font-size: 12px; float: right;
}
    
.itemDate {
  font-size: 0.9em;
}

.itemTitle {
  font-size: 1.1em;
  font-weight: bold;
}

#collection1 ul.feedEkList {
  list-style: none !important;
  margin-left: 0 !important;
}
ul.feedEkList li{
  margin: 0 0 10px 0;
  padding-bottom: 10px;
}
/* page layout adjustments */
.pagetype-proxied #content-block{
  width:100% !important; /* was 961px */
}
#col-3{
  display:none;
}
/* top nav */
/* #header .bar-inner, #footer .footer-group{
  background-color: #8DC958 !important;
}
#header .header-buttons a{
  color:navy;
}
*/
#header .header-qs input{
  padding:3px 5px !important;
}
#header .header-qs {
  top: 142px;
}
   /* hide navigation 
.header-buttons, #authstring ul, form.searchbox {
  display: none;
}
.bar{
  height:10px !important;
}
*/
/* page content */
#header #hdr-login, #header .header-qs,
.pagetype-proxied #content-block{
  border-right:none;
  border-left:none;
}
.hw-gen-page a:hover{
  border-bottom:none !important;
  text-decoration:underline !important;
}
/* rss feed display */
.myRow{
  margin-bottom: 20px;
}
.section{
  font-size: 1.0em; 
}
.itemDate{
  font-size:11px;color:#AAAAAA;
}
.itemContent p{
  margin:0;
}
/* ads */
.myLeaderAd{
  border-bottom: 1px solid #e2e2e2;
  height: 90px;
  padding-bottom: 10px;
  width: 100%;
}
.myAd{
  float:right;
  margin-left:30px;
}
/* videos */

.videoBlock{
  line-height: 15px;
  margin:0 20px 15px 0;
  position:relative;
  
}
.videoBlock a{
  font-size: 11px;
  line-height: 1.3em;
}

.vtitle{
    display:block;
    display: -webkit-box;
  -webkit-line-clamp: 2;
  -webkit-box-orient: vertical;  
  font-weight:bold;
  max-height:2.6em;
  line-height: 1.3em;
  overflow: hidden;
  margin-top: 4px;
  text-overflow: ellipsis;
  white-space: normal;
  word-wrap: break-word;
}
.author{
    display:block;
    display: -webkit-box;
  -webkit-line-clamp: 2;
  -webkit-box-orient: vertical;  
  font-size: 11px;
  line-height: 1.3em;
  max-height: 2.5em;
  overflow: hidden;
  text-overflow: ellipsis;
  white-space: normal;
  word-wrap: break-word;
}
    
@media only screen and (max-width:800px){ /* for smaller screens */
#newsletterscreen{
  display:none;
}
td {
  display: inline-block;
  margin: 9px 4px;
}

}
@media only screen and (min-device-width: 1024px){  /* for desktop screens */
#divRss {
  width: 755px;
}
}
</style>
<div id="collection1">
  
<h2><a name="breastcancer"></a>Breast Cancer</h2>

  <ul class="feedEkList">
  
    <li>
  <div class="itemDate">7/6/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/9/1063.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer</a></div>
  <div class="itemContent">Libero Santarpia, Giulia Bottai, Catherine M. Kelly, Bal&aacute;zs Gy&odblac;rffy, Borbala Sz&eacute;kely, Lajos Pusztai</div>
      <p>This review summarizes the current genomic portrait of breast cancer, focusing on genetic aberrations that are actively being targeted with investigational drugs. The importance of administering investigational targeted therapies, or off-label use of approved targeted drugs, in the context of a formal clinical trial or registry programs to facilitate learning about the clinical utility of tumor target profiling is emphasized.</p>
  </li>
  
<h2><a name="diagnostics"></a>Cancer Diagnostics and Molecular Pathology</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">10/24/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/1/89.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing</a></div>
  <div class="itemContent">Brianna Barsanti-Innes, Spencer Phillips Hey, Jonathan Kimmelman</div>
    <p>Research activities for a biomarker that has been in development for at least 12 years-excision repair cross-complement group 1 protein, as a biomarker for predicting clinical benefit with platinum-based chemotherapy in non-small cell lung cancer-were systematically mapped.</p>
  </li>
  </ul>

  
<h2><a name="endocrinology"></a>Endocrinology</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">2/16/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/3/255.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions</a></div>
  <div class="itemContent">Pierre Vanden Borre, Alexa B. Schrock, Peter M. Anderson, John C. Morris III, Andreas M. Heilmann, Oliver Holmes, Kai Wang, Adrienne Johnson, Steven G. Waguespack, Sai-Hong Ignatius Ou, Saad Khan, Kar-Ming Fung, Philip J. Stephens, Rachel L. Erlich, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali</div>
    
    <p>Comprehensive genomic profiling (CGP) identified diverse clinically relevant genomic alterations in pediatric, adolescent, and young adult patients with thyroid carcinoma, including 83% (34/41) of papillary thyroid carcinoma cases harboring activating kinase mutations or activating kinase rearrangements. These genomic observations and index cases exhibiting clinical benefit from targeted therapy suggest that young patients with advanced thyroid carcinoma can benefit from CGP and rationally matched targeted therapy.
      
      </p>
  </li>
  </ul>


<h2><a name="gastrointestinal"></a>Gastrointestinal Cancer</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">7/13/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/10/1200.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade</a></div>
  <div class="itemContent">Valerie Lee, Adrian Murphy, Dung T. Le, Luis A. Diaz, Jr.</div>
  <p>In this review article, the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in a number of tumor types, including those that are highly sensitive to PD-1 blockade, are discussed.</p>
  
  </li>
  </ul>
  
<h2><a name="genitourinary"></a>Genitourinary Cancer</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">2/16/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/12/1427.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer</a></div>
  <div class="itemContent">Emmanuel S. Antonarakis, Chandtip Chandhasin, Erica Osbourne, Jun Luo, Marianne D. Sadar, Frank Perabo</div>
<p>This article discusses N-terminal domain (NTD) inhibition as a novel concept in the field of androgen receptor (AR)-directed therapies for prostate cancer. AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity and as a result, may affect a broader AR population, including mutational and splice variant ARs.</p>
  </li>
  </ul>

 
<h2><a name="globalhealth"></a>Global Health and Cancer</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">6/10/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/7/832.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Founder and Recurrent Mutations in <em>BRCA1</em> and <em>BRCA2</em> Genes in Latin American Countries: State of the Art and Literature Review</a></div>
  <div class="itemContent">Carlos Andr&eacute;s Ossa, Diana Torres</div>
    <p>This review provides an update on the state of the art in founder mutations and some recurrent mutations recently described in Latin America. The relative proportion of each genetic component varies throughout Hispanic populations, and the presence of founder mutations in specific population groups represents a cost-effective approach to analysis.</p>
  </li>
  </ul>

  
<h2><a name="gynecologic"></a>Gynecologic Oncology</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">3/17/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/4/450.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Risk-Reducing Strategies for Ovarian Cancer in <em>BRCA</em> Mutation Carriers: A Balancing Act</a></div>
  <div class="itemContent">Roi Tschernichovsky, Annekathryn Goodman</div>
    <p>The role of bilateral salpingo-oophorectomy in BRCA mutation carriers and alternative interventions in risk reduction of ovarian cancer is reviewed. The efficacy and pitfalls of risk-reducing bilateral salpingo-oophorectomy are summarized, as well as its effect on quality of life and alternative preventative strategies.</p>
  </li>
  
    <li>
  <div class="itemDate">3/10/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/4/416.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <em>CDKN2A</em> Alteration</a></div>
  <div class="itemContent">Julia A. Elvin, Laurie M. Gay, Rita Ort, Joseph Shuluk, Jennifer Long, Lauren Shelley, Ronald Lee, Zachary R. Chalmers, Garrett M. Frampton, Siraj M. Ali, Alexa B. Schrock, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Richard Frank</div>
      <p>A patient with uLMS harboring a <em>CDKN2A</em> mutation experienced clinical benefit from treatment with palbociclib, and genomic analysis of 279 uterine leiomyosarcoma (uLMS) samples revealed that 19% of patients had mutations affecting the cyclin-dependent kinase (CDK) pathway. These observations provide a rationale for a clinical trial investigating treatment with CDK pathway inhibitors for uLMS harboring relevant genomic alterations.</p>
  </li>
  
    <li>
  <div class="itemDate">3/28/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/5/586.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer</a></div>
  <div class="itemContent">Eileen E. Parkes, Richard D. Kennedy</div>
      <p>To identify fully the ovarian cancer patient population that would benefit from poly(ADP-ribose) polymerase (PARP) inhibitors, predictive biomarkers are required. Additionally, better understanding of the toxicity profile is needed if PARP inhibitors are to be used in the curative, rather than the palliative, setting. The development of PARP inhibitors in phase I–III clinical trials, approval for these agents, mechanisms of resistance, and outstanding issues were reviewed.</p>
  </li>
  </ul>

<h2><a name="lung"></a>Lung Cancer</h2>

<ul class="feedEkList">
  <li>
  <div class="itemDate">11/7/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/1/3.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression</a></div>
  <div class="itemContent">Mark A. Socinski, Liza C. Villaruz, Jeffrey Ross</div>
    <p>Until recently, options were limited for patients with non-small cell lung cancer who progressed while receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), but improvements in molecular profiling and the approval of osimertinib afford the opportunity for improved outcomes in many patients with the <em>EGFR</em> T790M mutation. This article explains the options available after progression on initial EGFR TKI therapy and the importance of molecular testing at progression in making treatment decisions.</p>
  </li>
  
    <li>
  <div class="itemDate">8/17/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/1/81.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer</a></div>
  <div class="itemContent">Benjamin Herzberg, Meghan J. Campo, Justin F. Gainor</div>
      <p>Immune checkpoint inhibitors have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). Programmed cell death protein-1/programmed cell death ligand-1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel, effectively establishing a new standard of care in NSCLC. An overview of the rationale for checkpoint inhibitors in lung cancer, recent clinical trial data, and the need for predictive biomarkers is provided.</p>
  </li>
  
    <li>
  <div class="itemDate">11/2/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/12/1450.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Targeting the KRAS Pathway in Non-Small Cell Lung Cancer</a></div>
  <div class="itemContent">Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao, Natasha B. Leighl</div>
      <p>An overview is presented of the KRAS pathway in lung cancer and related therapeutic strategies under investigation. <em>KRAS</em> is one of the most frequently mutated genes in non-small cell lung cancer (NSCLC). Potential approaches for the treatment of <em>KRAS</em>-mutant NSCLC include direct inhibition of KRAS protein, inhibition of KRAS regulators, alteration of KRAS membrane localization, and inhibition of effector molecules downstream of mutant KRAS.</p>
  </li>
  </ul>
  
  
<h2><a name="melanoma"></a>Melanoma and Cutaneous Malignancies</h2>

<ul class="feedEkList">  
    <li>
  <div class="itemDate">7/8/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/10/1230.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents</a></div>
  <div class="itemContent">Jeffrey S. Weber, Michael Postow, Christopher D. Lao, Dirk Schadendorf</div>
      <p>This review focuses on the management of immune-related adverse events (irAEs) after treatment with anti-programmed death-1 antibodies as monotherapy or in combination in patients with advanced melanoma. A better understanding of the management of irAEs will help ensure the safe and appropriate use of these agents in melanoma and other tumor types.</p>
  </li>
  
    <li>
  <div class="itemDate">8/10/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/10/1218.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma</a></div>
  <div class="itemContent">Mario E. Lacouture, Brigitte Dr&eacute;no, Paolo Antonio Ascierto, Reinhard Dummer, Nicole Basset-Seguin, Kate Fife, Scott Ernst, Lisa Licitra, Rogerio I. Neves, Ketty Peris, Susana Puig, Jonas Sokolof, Aleksandar Sekulic, Axel Hauschild, Rainer Kunstfeld</div>
      <p>Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article.</p>
  </li>
  </ul>  

<h2><a name="radiation"></a>Radiation Oncology</h2>

<ul class="feedEkList">  
    <li>
  <div class="itemDate">1/13/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/2/244.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases</a></div>
  <div class="itemContent">Fabio Ynoe Moraes, Neil K. Taunk, Gustavo Nader Marta, John H. Suh, Yoshiya Yamada</div>
            <p>Stereotactic surgery (SRS) has revolutionized local treatment of brain metastases. Targeted therapies, including small-molecule inhibitors and monoclonal antibodies that target cancer cell metabolism or angiogenesis, have transformed managing systemic disease. This article discusses reported and ongoing clinical trials assessing the safety and efficacy of targeted therapy during SRS.</p>
  </li>
  </ul>  

      
  
<h2><a name="sarcomas"></a>Sarcomas</h2>

<ul class="feedEkList">  
    <li>
  <div class="itemDate">7/8/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/8/1002.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review</a></div>
  <div class="itemContent">Mohamad Farid, Joanne Ngeow</div>
<p>This review describes in detail selected heritable cancer predisposition syndromes that are known to be associated with sarcomas. Situating sarcomas within the genetic endowment of particular patients will enable clinicians to better manage the patient as a whole.</p>
  </li>
  </ul>  
  
<h2><a name="precision"></a>Precision Medicine Clinic</h2>

<ul class="feedEkList">  
    <li>
  <div class="itemDate">8/22/2016</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/21/9/1035.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Metastatic Breast Cancer With <em>ESR1</em> Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital</a></div>
  <div class="itemContent">Aditya Bardia, John A. Iafrate, Tilak Sundaresan, Jerry Younger, Valentina Nardi</div>
      <p>
This article reviews the key considerations involved in clinical decision making while reviewing a molecular genotyping report. The article presents the case of a 67-year-old postmenopausal female with metastatic estrogen receptor-positive breast cancer, whose tumor progressed on multiple endocrine therapies.
</p>
  </li>
  
    <li>
  <div class="itemDate">5/2/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/22/5/497.full" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">DNA Polymerase &epsilon; Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity</a></div>
  <div class="itemContent">Enrico Castellucci, Tianfang He, D. Yitzchak Goldstein, Balazs Halmos, Jennifer Chuy</div>
      <p>Two cases of metastatic colorectal cancer with a <em>POLE</em> mutation, both of which were ultramutated and microsatellite stable, are presented and discussed from the standpoint of the basic biochemical mechanisms leading to a unique phenotype in <em>POLE</em> deficiency,  the challenges faced with interpreting the genomic profiling of tumors in this important subset of patients, and the potential clinical implications.</p>
  </li>
  
    <li>
  <div class="itemDate">5/15/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/early/2017/05/12/theoncologist.2016-0376.abstract" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">Detection of an <em>ALK</em> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA</a></div>
  <div class="itemContent">Andrea Z. Lai, Alexa B. Schrock, Rachel L. Erlich, Jeffrey S. Ross, Vincent A. Miller, Evgeny Yakirevich, Siraj M. Ali, Fadi Braiteh</div>
      <p>The case of a patient with metastatic colorectal cancer is presented. This report is the first instance of an <em>ALK</em> fusion in colorectal cancer detected using a ctDNA assay.</p>
  </li>
  
    <li>
  <div class="itemDate">5/15/2017</div>
  <div class="itemTitle"><a href="http://theoncologist.alphamedpress.org/content/early/2017/05/12/theoncologist.2017-0054.abstract" target="_blank" onclick="window.open(this.href); return false;" onkeypress="window.open(this.href); return false;">A Case of Metastatic Atypical Neuroendocrine Tumor with <em>ALK</em> Translocation and Diffuse Brain Metastases</a></div>
  <div class="itemContent">Victoria E.Wang, Lauren Young, Siraj Ali, Vincent Miller, Anatoly Urisman, John Wolfe, Trever G. Bivona, Bertil Damato, Shannon Fogh, Emily Bergsland</div>
      <p>A challenge in precision medicine is the identification of actionable driver mutations. Alterations can be  identified within the tumor tissue, by small biopsy or fine-needle aspirates, or by noninvasive methods, such as circulating tumor cells or circulating tumor DNA. This article presents a case of metastatic atypical neuroendocrine tumor of the bone and brain, for which circulating tumor DNA analysis found an <em>ALK</em> translocation.</p>
  </li>
  </ul>  
    
<div id="end-content-marker"><!-- end of content marker div --></div>


</body>
</html>
